A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects.

Trial Profile

A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2014

At a glance

  • Drugs Evacetrapib (Primary) ; Moxifloxacin
  • Indications Atherosclerosis; Dyslipidaemias
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 26 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top